Description
Release form
Intravenous solution.
Packing
10 ampoules.
Pharmacological action
Riboxin Bufus – a metabolic agent, the precursor of ATP has antihypoxic, metabolic and antiarrhythmic effects. Increases the energy balance of the myocardium, improves coronary circulation, prevents the effects of intraoperative renal ischemia. It activates the metabolism of pyruvic acid to ensure the normal process of tissue respiration, and also promotes the activation of xanthine dehydrogenase. It stimulates the synthesis of nucleotides, enhances the activity of some enzymes of the Krebs cycle. Penetrating into cells, it increases the energy level, has a positive effect on metabolic processes in the myocardium, increases the force of contractions of the heart and contributes to a more complete relaxation of the myocardium in diastole, as a result of which the CRI increases. Reduces platelet aggregation, activates tissue regeneration (especially the myocardium and gastrointestinal mucosa).
Indications
ischemic heart disease (myocardial infarction, coronary insufficiency, cardiac arrhythmias), congenital and acquired heart defects, rheumatic heart diseases, cardiomyopathies of various origins, coronary atherosclerosis, digitalis intoxication, myocarditis, myocarditis, dystrophic myocarditis, severe physical exertion, infectious and endocrine genesis), liver disease (acute and chronic hepatitis, cirrhosis of the liver, alcohol and drug damage to the liver, fatty degeneration of the liver), peptic ulcer of the stomach and duodenum, uroproporphyria. Poisoning drugs, alcoholism, radiation leukopenia (prevention), operations on an isolated kidney (as a means of pharmacological protection when temporarily turning off the blood circulation of the operated organ).
Contraindications
Hypersensitivity, hyperuricemia, gout.
Special instructions
Riboxin is not used for emergency correction of cardiac abnormalities.
Composition
Active ingredient: inosine.
Dosage and administration of
I / O (slow, jet or drip – 40-60 drops / min): start with 200 mg (10 ml of 2% solution) once a day, then, with good tolerance, the dose is increased to 400 mg 1-2 times a day. The duration of treatment is 10-15 days. In acute rhythm and conduction disturbances, a single injection of 200-400 mg is permissible. For pharmacological protection of ischemia-treated kidneys, i.v. is administered in a single dose in a single dose of 1.2 g (60 ml of a 2% solution) 5-15 minutes before clamping the renal artery, and then another 0.8 g (40 ml of a 2% solution) immediately after restoration of blood circulation. For iv drip, a 2% solution is diluted in a 5% dextrose solution or 0.9% NaCl solution (up to 250 ml).
Side effects of
Hyperuricemia, exacerbation of gout (with prolonged allergic reaction, high-pressure, high-temperature pain, hyperemia of the skin).
Drug interaction
When used as part of complex therapy, Riboxin helps increase the effectiveness of antiarrhythmic, antianginal and inotropic drugs.
Clinically significant interaction of Riboxin with drugs of other groups is not described.
Overdose
No overdose cases reported so far.
Storage Conditions
In a dark place at 15-25 ° C.
The Expiration of
is 3 years.
Active ingredient
Inosine
conditions granted through pharmacies
In retseptu
Dosage form
solution for infusions
